Looking for Oncology Payoff, Astellas Makes Hostile Bid for Tarceva Maker OSI

Japan's second-biggest pharma offers $3.5 billion to OSI shareholders after 13 months of rejection by the target's management.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet